Edaravone in COVID-19

Phase 3

• Conditions: Patients with COVID-2019.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20200317046797N6
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with COVID-19-induced pneumonia confirmed with Polymerase chain reaction (PCR)
Patients with COVID-19-induced pneumonia confirmed with chest CT scan results
18 to 80 years old
Patients with acute respiratory distress syndrome (ARDS) according to Berlin ARDS criteria

Exclusion Criteria

Patients who are participating in other drug clinical trials
Pregnant or lactating women
Patient with drug allergy
Patients on mechanical ventilation
Patients with expected survival duration< 24 h

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hospitalization days. Timepoint: At baseline and discharge time. Method of measurement: Counting the days.;Need for mechanical ventilation. Timepoint: From baseline to discharge time. Method of measurement: Observation and documents.;Condition of discharge (death or recovery). Timepoint: End of hospitalization. Method of measurement: Observation and documents.